Literature DB >> 27216835

Optimal dosing of intravenous ketamine for procedural sedation in children in the ED-a randomized controlled trial.

Nirupama Kannikeswaran1, Mary Lieh-Lai2, Monica Malian3, Bo Wang4, Ahmad Farooqi5, Mark G Roback6.   

Abstract

OBJECTIVE: The objective of the study is to compare need for redosing, sedation efficacy, duration, and adverse events between 3 commonly administered doses of parenteral ketamine in the emergency department (ED).
METHODS: We conducted a prospective, double-blind, randomized controlled trial on a convenience sample of children 3 to 18years who received intravenous ketamine for procedural sedation. Children from each age group (3-6, 7-12, and 13-18years) were assigned in equal numbers to 3 dosing groups (1, 1.5, and 2mg/kg) using random permuted blocks. The primary outcome measure was need for ketamine redosing to ensure adequate sedation. Secondary outcome measures were sedation efficacy, sedation duration, and sedation-related adverse events.
RESULTS: A total of 171 children were enrolled of whom 125 (1mg/kg, 50; 1.5mg/kg, 35; 2mg/kg, 40) received the randomized dose and were analyzed. The need for ketamine redosing was higher in the 1mg/kg group (8/50; 16.0% vs 1/35; 2.9% vs 2/40; 5.0%). There was no significant difference in the median Ramsay sedation scores (5.5 [interquartile range {IQR}, 4-6] vs 6 [IQR, 4-6] vs 6 [IQR, 5-6]), FACES-R score (0 [IQR, 0-4] vs 0 [IQR, 0-0] vs 0 [IQR, 0-0]), sedation duration in minutes (23 [IQR, 19-38] vs 24.5 [IQR, 17.5-34.5] vs 23 [IQR, 19-29]), and adverse events (10.0% vs 14.3% vs 10.0%) between the 3 dosing groups. Physician satisfaction was lower in the 1mg/kg group (79.6% vs 94.1% vs 97.3%).
CONCLUSIONS: Adequate sedation was achieved with all 3 doses of ketamine. Higher doses did not increase the risk of adverse events or prolong sedation. Ketamine administered at 1.5 or 2.0mg/kg intravenous required less redosing and resulted in greater physician satisfaction.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27216835     DOI: 10.1016/j.ajem.2016.03.064

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  8 in total

1.  Fractional calculus in pharmacokinetics.

Authors:  Pantelis Sopasakis; Haralambos Sarimveis; Panos Macheras; Aristides Dokoumetzidis
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-10-03       Impact factor: 2.745

2.  Analysis of Plastic Surgery Consultations in a High-Volume Paediatric Emergency Department: A Quality Improvement Initiative.

Authors:  Kathrin Neuhaus; Emily S Ho; Nelson Low; Christopher R Forrest
Journal:  Plast Surg (Oakv)       Date:  2020-11-10       Impact factor: 0.947

3.  Behavioral Changes in Children After Emergency Department Procedural Sedation.

Authors:  Jean I Pearce; David C Brousseau; Ke Yan; Keri R Hainsworth; Raymond G Hoffmann; Amy L Drendel
Journal:  Acad Emerg Med       Date:  2017-11-13       Impact factor: 3.451

4.  Intravenous Ketamine for Adolescents with Treatment-Resistant Depression: An Open-Label Study.

Authors:  Kathryn R Cullen; Palistha Amatya; Mark G Roback; Christina Sophia Albott; Melinda Westlund Schreiner; Yanan Ren; Lynn E Eberly; Patricia Carstedt; Ali Samikoglu; Meredith Gunlicks-Stoessel; Kristina Reigstad; Nathan Horek; Susannah Tye; Kelvin O Lim; Bonnie Klimes-Dougan
Journal:  J Child Adolesc Psychopharmacol       Date:  2018-07-13       Impact factor: 2.576

5.  Safety and Efficacy of Procedural Sedation and Analgesia in Pediatric Oncology Patients.

Authors:  Saba Laila Aslam; Anwar Haque; Muhammad Tariq Jamil; Madiha Ariff; Saad Nasir
Journal:  Cureus       Date:  2020-03-28

6.  Results from the Adverse Event Sedation Reporting Tool: A Global Anthology of 7952 Records Derived from >160,000 Procedural Sedation Encounters.

Authors:  Keira P Mason; Mark G Roback; David Chrisp; Nicole Sturzenbaum; Lee Freeman; David Gozal; Firoz Vellani; David Cavanaugh; Steven M Green
Journal:  J Clin Med       Date:  2019-12-01       Impact factor: 4.241

7.  Determining a Bayesian predictive power stopping rule for futility in a non-inferiority trial with binary outcomes.

Authors:  Anna Heath; Martin Offringa; Petros Pechlivanoglou; Juan David Rios; Terry P Klassen; Naveen Poonai; Eleanor Pullenayegum
Journal:  Contemp Clin Trials Commun       Date:  2020-04-08

8.  The intranasal dexmedetomidine plus ketamine for procedural sedation in children, adaptive randomized controlled non-inferiority multicenter trial (Ketodex): a statistical analysis plan.

Authors:  Anna Heath; Juan David Rios; Eleanor Pullenayegum; Petros Pechlivanoglou; Martin Offringa; Maryna Yaskina; Rick Watts; Shana Rimmer; Terry P Klassen; Kamary Coriolano; Naveen Poonai
Journal:  Trials       Date:  2021-01-06       Impact factor: 2.279

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.